1[16]Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study[J]. J Clin Pharmacol, 2002,42:395-402
2[17]Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis[J]. Clin Infect Dis, 2002,34:563-571
3[18]Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. N Engl J Med, 2002 8,347:408-415
4[19]Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients[J]. Clin Infect Dis, 2001, 33:1447-1454
5[20]Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, et al. Voriconazole for the treatment of S. apiospermum and S. prolificans infection[abstract 305]. In: Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). 2000
6[21]Perfect JR, Lutsar I, Gonzalex-Ruiz A. Voriconazole for the treatment of resistant and rare fungal pathogens [abstract 303]. In: Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). 2000
7[22]Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole[J]. Br J Ophthalmol, 2000,84:932-933
8[1]Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System[J]. J Infect Dis. 1993,167:1247-1251
9[2]Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital[J]. J Infect. 1996,33:23-32
10[3]Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance[J]. Am J Med, 1996,100:617-623
